Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications

IF 3.6 3区医学 Q2 ENDOCRINOLOGY & METABOLISM

Journal of Diabetes Investigation Pub Date : 2026-10-01 Epub Date: 2026-07-25 DOI:10.1111/jdi.70407

Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami

{"title":"Comparison between liraglutide and dulaglutide on the incidence or progression of eye and kidney complications","authors":"Aki Katamine, Junko Oya, Yuichiro Kondo, Yukiko Hasegawa, Tomoko Nakagami","doi":"10.1111/jdi.70407","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>To evaluate and compare the risk of diabetic retinopathy and kidney disease between once-daily liraglutide and once-weekly dulaglutide in Japanese participants with type 2 diabetes (T2D).</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>A total of 341 participants newly initiated on once-daily liraglutide 0.9 mg or once-weekly dulaglutide 0.75 mg between 2015 and 2020 were included in this study. We used propensity score-based inverse probability of treatment weighting to adjust for baseline characteristics between the two groups. The participants were divided into three cohorts according to retinopathy, albuminuria, and glomerular filtration rate (GFR). The primary outcomes were the incidence or progression of diabetic retinopathy or kidney disease (albuminuria or reduced estimated GFR (eGFR) <60 mL/min/1.73 m<sup>2</sup>). The incidence rate and risk of outcomes were compared between the two groups using Poisson regression and Cox proportional hazard models. [Correction added on September 7, 2026, after first online publication: The total number of participants in the Materials and Methods section has been corrected from 331 to 341.]</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Over a mean follow-up of 4.4 and 3.6 years in the liraglutide and dulaglutide groups, respectively, there were no differences between the two groups in terms of the risk of incidence of retinopathy and reduced GFR (hazard ratio (HR): 0.98 [0.60–1.60] and 0.82 [0.36–1.84]). Dulaglutide showed a lower incidence or progression rate but similar risk of albuminuria compared to liraglutide (54.7 vs 25.8 per 1,000 person-years (<i>P</i> = 0.04), HR: 0.51 [0.25–1.05]).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Our study showed that once-daily liraglutide and once-weekly dulaglutide have similar risks for retinopathy, albuminuria, and reduced GFR.</p>\n </section>\n </div>","PeriodicalId":51250,"journal":{"name":"Journal of Diabetes Investigation","volume":"17 10","pages":"1726-1734"},"PeriodicalIF":3.6000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13401126/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Diabetes Investigation","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jdi.70407","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/7/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aims

To evaluate and compare the risk of diabetic retinopathy and kidney disease between once-daily liraglutide and once-weekly dulaglutide in Japanese participants with type 2 diabetes (T2D).

Materials and Methods

A total of 341 participants newly initiated on once-daily liraglutide 0.9 mg or once-weekly dulaglutide 0.75 mg between 2015 and 2020 were included in this study. We used propensity score-based inverse probability of treatment weighting to adjust for baseline characteristics between the two groups. The participants were divided into three cohorts according to retinopathy, albuminuria, and glomerular filtration rate (GFR). The primary outcomes were the incidence or progression of diabetic retinopathy or kidney disease (albuminuria or reduced estimated GFR (eGFR) <60 mL/min/1.73 m²). The incidence rate and risk of outcomes were compared between the two groups using Poisson regression and Cox proportional hazard models. [Correction added on September 7, 2026, after first online publication: The total number of participants in the Materials and Methods section has been corrected from 331 to 341.]

Results

Over a mean follow-up of 4.4 and 3.6 years in the liraglutide and dulaglutide groups, respectively, there were no differences between the two groups in terms of the risk of incidence of retinopathy and reduced GFR (hazard ratio (HR): 0.98 [0.60–1.60] and 0.82 [0.36–1.84]). Dulaglutide showed a lower incidence or progression rate but similar risk of albuminuria compared to liraglutide (54.7 vs 25.8 per 1,000 person-years (P = 0.04), HR: 0.51 [0.25–1.05]).

Conclusions

Our study showed that once-daily liraglutide and once-weekly dulaglutide have similar risks for retinopathy, albuminuria, and reduced GFR.

查看原文本刊更多论文

利拉鲁肽与杜拉鲁肽对眼、肾并发症发生率及进展的比较。

目的：评估和比较日本2型糖尿病（T2D）患者每日一次利拉鲁肽和每周一次杜拉鲁肽之间糖尿病视网膜病变和肾脏疾病的风险。材料和方法：2015年至2020年期间，共有331名新开始服用每日一次0.9 mg利拉鲁肽或每周一次0.75 mg杜拉鲁肽的参与者被纳入本研究。我们使用基于倾向评分的治疗加权逆概率来调整两组之间的基线特征。参与者根据视网膜病变、蛋白尿和肾小球滤过率（GFR）分为三组。主要结局是糖尿病视网膜病变或肾脏疾病（蛋白尿或估计GFR (eGFR) 2降低）的发生率或进展。采用泊松回归和Cox比例风险模型比较两组的发生率和结局风险。结果：利拉鲁肽组和杜拉鲁肽组的平均随访时间分别为4.4年和3.6年，两组在视网膜病变发生率和GFR降低的风险方面没有差异（风险比（HR）： 0.98[0.60-1.60]和0.82[0.36-1.84]）。与利拉鲁肽相比，杜拉鲁肽的发病率或进展率较低，但蛋白尿的风险相似（54.7 vs 25.8 / 1000人年（P = 0.04）， HR: 0.51[0.25-1.05]）。结论：我们的研究表明，每日一次利拉鲁肽和每周一次杜拉鲁肽在视网膜病变、蛋白尿和GFR降低方面具有相似的风险。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Diabetes Investigation ENDOCRINOLOGY & METABOLISM-

CiteScore

6.50

自引率

9.40%

发文量

218

审稿时长

6-12 weeks

期刊介绍： Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. Embracing clinical and experimental research in diabetes and related areas, the Journal of Diabetes Investigation includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcome. Journal of Diabetes Investigation is indexed by Science Citation Index Expanded (SCIE).